ALKBH5 has been shown to be responsible for tumor proliferation in different cancers, including breast cancer (117), glioblastoma (118) and LADC (119), so its inhibition can yield good clinical outcomes if implemented. This evidence concerns the gene ALKBH5 and cancer.